Immune Checkpoint Inhibitors Market to Witness 24.1% Annualised Growth, Predicts Roots Analysis

LONDON

Roots Analysis has announced the addition of “Immune Checkpoint Inhibitors Market, 2014-2024” report to their offering. The study offers a comprehensive view of the emerging market of CTLA-4, PD-1, PD-L1 and several novel immune checkpoint inhibitors (IDO-1, IDO-2, KIR, OX40, CD70, LAG-3 and more).

Apurva Bhardwaj, the principal analyst, said, “Owing to the highly responsive nature of the market, marked by the presence of new entrants and established companies, the future looks highly promising. The study includes valuable insights encompassing the prevailing competitive market of oncology, the common platform created by partnering activities and the forecast for marketed/late stage development products.”

Bhardwaj further stated, “The market is currently characterized by the presence of three marketed drugs and 25 drugs in clinical development.

• BMS, with seven immune checkpoint inhibitors, is the leading player. Many university spin-offs have recently emerged; their early stage research has been backed by venture funding.
• Amongst the novel immune checkpoint inhibitors, IDO inhibitors are the most sought after. These novel checkpoints have paved the way for smaller firms to enter the immuno-oncology market.
• Clinical trial collaborations, to evaluate immune checkpoint inhibitors as combination therapies, have been very common; 2014 has already seen 12 such collaborations for a number of molecules.”

Amongst other things, the report covers:

• Detailed discussion on the subtypes of the immune checkpoint inhibitors (CTLA-4, PD-1/PD-L1 and novel inhibitors).
• Current market outlook, along with the key drivers and restraints, likely to influence the future growth.
• Competitive landscape with a view on existing treatments available for same indications.
• Partnering activities which are likely to unfold as the market matures further.

With several blockbusters in the pipeline, Roots Analysis predicts the market to grow at a CAGR of 24.1% over the coming decade.

The 192 page report includes detailed profiles and an assessment of the clinical research pipeline of many companies mentioned below. In addition, there are several other companies which have molecules in discovery/preclinical stages.

• BMS
• AstraZeneca
• Merck
• Roche/Genentech
• Incyte Corporation
• NewLink Genetics
• arGEN-X
• Seattle Genetics
• Pfizer
• MacroGenics
• Celldex Therapeutics
• CureTech
• Immutep
• Innate Pharma
• GSK
• GITR

For additional details, please visit http://www.rootsanalysis.com/reports/market-reports/view_document/immune-checkpoint-inhibitors-market-2014-2024/73.html or email at sales@rootsanalysis.com.